Forward Science Technologies, creators of OralID, announce biopsy service

Over two years ago, Forward Science Technologies LLC (FST) received FDA clearance for theOralIDoral cancer screening device. Since then, FST has continued to focus on the oral oncology market, providing technologies and services to combat the rise of oral cancer incidences. Biopsy is the “gold standard” for oral cancer diagnosis, and in April, FST launched PathID, a nationwide biopsy service.

PathID is a biopsy service that is focused on the uniqueness of the oral cavity. Contrary to most pathology services, PathID will be read exclusively by oral pathologists with detailed pathology results so that each patient can be better treated. Free case consultations will come with each PathID biopsy reading to enable clinicians to understand the diagnosis and decide on a treatment plan for each patient.

With the addition of PathID, FST now has multiple testing options for dental offices to use during efforts for early diagnosis: CytID, a liquid based cytology swab; hpvID, an oral HPV point-in-time test; phID, a chairside pH test; and now, PathID, a nationwide biopsy service. All of these services are offered by ID Laboratories, a division of FST.

“With the launch of PathID, we are now able to provide a diagnostic service to go along with our screening device, OralID,” said Brian Pikkula, Ph.D., president and CTO of FST. “It is a great feeling to offer [dentists] so many options to utilize in their [offices], all with the goal of early discovery for better outcomes.”